Our Team

Paul Brennan has over 30 years of experience in the pharmaceutical and biotech industries working in leadership roles in general management, corporate strategy, commercial planning, business development and regulatory affairs in Canada, Sweden, the United Kingdom, and the United States. Most recently Mr. Brennan’s experiences include senior business development and management positions in various biotech companies, including Aquinox Pharmaceuticals, Arbutus Biopharma, Aspreva Pharmaceuticals, and AnorMED Inc. Mr. Brennan has a comprehensive list of business development and licensing transactions, totalling over $3 billion in value: he played key roles in the merger of Tekmira Pharmaceuticals and OnCore BioPharma to create Arbutus Biopharma, in the sale of Aspreva Pharmaceuticals to Vifor Pharma for $915 million and in the sale of AnorMED to Genzyme for $580 million. Prior to working in biotech Mr. Brennan held senior roles in Business Development and Regulatory Affairs at AstraZeneca. Mr. Brennan holds a MSc in Physiology, and a BSc (Hons) in Life Sciences from Queen’s University in Kingston, Ontario.

Dan Mikol, MD, PhD, has over 25 years of experience in the pharmaceutical industry and as a practicing neurologist conducting clinical research. For 12 years, he was an active clinician and clinical researcher in the Department of Neurology at the University of Michigan, specializing in the treatment of multiple sclerosis, where he rose to the level of Associate Professor. For the past 13 years, Dr. Mikol has had leadership roles in neuroscience clinical development and medical affairs. Prior to joining NervGen, he was the clinical development head of neuroscience and nephrology therapeutic areas, and the pan-therapeutic area molecular genetics team at Amgen. He was instrumental in the approval of Aimovig for migraine prevention in 2018. Prior to Amgen, Dr. Mikol was the development lead for Tysabri at Biogen and supported the Japan approval of Tysabri for relapsing multiple sclerosis in 2014. Prior to that, Dr. Mikol had senior clinical development and medical affairs roles in neuroscience at Novartis and EMD Serono. Dr. Mikol was educated at the University of Chicago for both his MD and PhD, and was a Fulbright Scholar, Immunological Research, Ludwig Maximilian University of Munich, Germany. He held a staff physician role treating patients for 12 years at The University of Michigan, Department of Neurology.

Bill Adams has over 25 years of strategic financial management experience that includes mergers and acquisitions, operations and capital markets in both Canada and the U.S., as well as corporate and operational finance having held a number of executive positions with high-growth technology and life sciences companies, including Chief Financial Officer roles at Anandia Laboratories Inc., Response Biomedical Corp., CellFor Inc., and AnorMED Inc. He had a leading role in the sale of AnorMED to Genzyme for $580 million and was instrumental in the sale of Anandia in 2018 for $118 million. Mr. Adams has been responsible for completing over $250 million in public and private equity financing, including listing on the TSX and NASDAQ, and over $750 million in mergers and acquisitions and technology licensing transactions. Mr. Adams is a Chartered Professional Accountant, CA and holds a Bachelor of Commerce from the University of British Columbia.

Nana Collett has over 20 years experience managing biopharma product development programs from preclinical stage to Phase 3 across a range of therapeutic areas and modalities. Prior to joining NervGen, Ms. Collett has been an independent consultant and advisor to start-up companies. Prior to that, she was VP Program Management at Genevant Sciences and a member of the start-up leadership team where she was responsible for development of a pipeline of over 10 internal and partnered RNA therapeutic products. She previously spent nine years with NASDAQ-listed company Arbutus Biopharma (formerly Tekmira Pharmaceutical), most recently as VP Project Management responsible for all development stage programs and alliances. Prior to that, she held diverse roles at commercial stage biotech company QLT in project management, new product planning, and business development. Ms. Collett has a BSc (Honours) in Biology from University of British Columbia, an M.S. in Ecosystem Science from the University of Washington, and an MBA in Management of Technology from Simon Fraser University.

Bill Radvak is a co-founder of NervGen and has been the CEO and director of multiple start-up companies. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company, which he led from its inception to a 90-employee sales and manufacturing company. Mr. Radvak received his Bachelor of Applied Science degree from the University of British Columbia

Paul Brennan has over 30 years of experience in the pharmaceutical and biotech industries working in leadership roles in general management, corporate strategy, commercial planning, business development and regulatory affairs in Canada, Sweden, the United Kingdom, and the United States. Most recently Mr. Brennan’s experiences include senior business development and management positions in various biotech companies, including Aquinox Pharmaceuticals, Arbutus Biopharma, Aspreva Pharmaceuticals, and AnorMED Inc. Mr. Brennan has a comprehensive list of business development and licensing transactions, totalling over $3 billion in value: he played key roles in the merger of Tekmira Pharmaceuticals and OnCore BioPharma to create Arbutus Biopharma, in the sale of Aspreva Pharmaceuticals to Vifor Pharma for $915 million and in the sale of AnorMED to Genzyme for $580 million. Prior to working in biotech Mr. Brennan held senior roles in Business Development and Regulatory Affairs at AstraZeneca. Mr. Brennan holds a MSc in Physiology, and a BSc (Hons) in Life Sciences from Queen’s University in Kingston, Ontario.

 

Dr. Michael Abrams currently serves as the Chief Scientific Officer for Abdera Therapeutics Inc., a company developing therapeutic radiopharmaceuticals for cancer treatment. Previously, he held executive vice president roles at Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) (a biopharmaceutical company) in 2014 through 2016; was the VP Research & Development at CDRD Ventures Inc. (a drug commercialization company for Canada’s Centre for Drug Research and Development in Vancouver, British Columbia) in 2012 and 2013; and CEO of Inimex Pharmaceuticals Inc. (a drug development company) from 2009 to 2012. In addition, he was previously the founding President and Chief Executive Officer of AnorMED Inc. from 1996 to 2006. Dr. Abrams graduated with a BA in chemistry from Bowdoin College in Brunswick, Maine in 1978 and subsequently received his PhD in chemistry from the Massachusetts Institute in Technology in 1983.

 

Brian Bayley is a Director and the Executive Chairman of Earlston Investments, a private merchant bank, with transaction experience of over $2 billion. Previously, Mr. Bayley was CEO of Quest Capital and worked with the Vancouver Stock Exchange, now the TSX Venture Exchange. Mr. Bayley has over 30 years of public issuer experience, both as a director and officer, in numerous private and public companies.

Dr. Kaye is currently Chief Medical Officer at Neurana Pharmaceuticals in San Diego, California. Prior to Neurana, Dr. Kaye served as CMO at Click Therapeutics, Axsome Therapeutics and Avanir Pharmaceuticals. Earlier in his career, Dr. Kaye held leadership positions at Scios Inc., InterMune and Pfizer Inc. Dr. Kaye earned an M.D., M.P.H. and B.S. at The George Washington University and was a Research Fellow at Harvard Medical School.

 

Dr. Punnett, co-founder of NervGen, is an accomplished angel investor who has been the director of multiple start-up companies. As a dental surgeon with a practice in British Columbia, Canada, he has extensive knowledge of medicine and physiology, including cell biology. Along with this knowledge, he has a deep passion for those suffering from spinal cord injury and other nerve-related challenges. Dr. Punnett is a Member of the College of Dental Surgeons of British Columbia, Member of the British Columbia Dental Association and Member of the Canadian Dental Association. He received his doctorate degree from the University of British Columbia.

Dr. Silver is the Professor of Neurosciences at Case Western Reserve University’s School of Medicine and adjunct Professor in the Department of Neurosurgery at the Cleveland Clinic Foundation. He is credited in over 180 publications and is the recipient of several prestigious awards, including the Ameritec Prize for significant accomplishments toward a cure for paralysis. In 2003 he was also honored with the Christopher Reeve-Joan Irvine Research Medal (The Reeve-Irvine Medal) for critical contributions that may lead to the promotion of repair of the damaged spinal cord. Dr. Silver is an active advisor to NervGen, and his lab continues to conduct studies in concert with other academic institutions and partners to advance and evolve intracellular sigma peptide

Colonel (ret.) Michael Davis, MD, FACS is recently retired after 26 years of military service, and has accumulated an extensive, rare knowledge base involving the clinical, scientific, operational and governmental programmatic domains. He has garnered numerous military and medical publications and awards, and serves as a reviewer for professional journals and is a Fellow of the American College of Surgeons. For the past seven years, Colonel (ret.) Davis has served in escalating Department of Defense programmatic roles as Deputy Commander, US Army Institute of Surgical Research, and culminating over the past three years, as Director, US Combat Casualty Care Research Program-the Department’s largest medical R&D program. With more than 30 years in the clinical and biomedical science field, Colonel (ret.) Davis provides services and expertise in trauma, regenerative/ restorative medicine, federal government relations, defense, health, cyber and national security.

Dr. Marta Hamilton is a veteran in drug development with expertise in pharmacokinetics, biomarkers, preclinical and clinical study design, as well as experience with multiple investigational new drug and new drug applications. Dr. Hamilton served in leadership and technical positions at Eli Lilly, Amgen, NeXstar Pharmaceuticals and Gilead Sciences, and most recently as Vice President, Preclinical Development and Clinical Pharmacology at OSI Pharmaceuticals.

A prolific start-up specialist, advisor, founder and angel investor to start-up companies, Mr. McAlister assists start-ups with raising capital and other activities. Over the past 30 years, Mr. McAlister has assisted over 25 early stage companies in various industries including biotechnology, enterprise software, and natural resources.

Ernest Wong has over 20 years of experience in the pharmaceutical and biotechnology industries. Dr. Wong led NervGen as President & CEO during the successful Initial Public Offering on the TSX-V and was instrumental in bringing NervGen’s technology and NVG-291 to Phase 1 readiness. Prior to NervGen, Dr. Wong held several executive positions in business development or corporate affairs at Accera, Piramal Imaging and YM BioSciences. His experiences also include executing business development transactions, managing partnerships and global clinical programs at OSI Pharmaceuticals and AnorMED.

Dr. George Perry is the current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio. He received his Bachelor of Arts degree in Zoology from University of California, Santa Barbara and his PhD in Marine Biology from the Scripps Institute of Oceanography, University of California, San Diego. Dr. Perry has received a number of awards for his research in the Alzheimer’s disease space, including the Denham Harman Research Award, the Senior Investigator Award from the College of Geriatric Psychoneuropharmacology and the Zenith and Temple Awards from the Alzheimer’s Association.

Dr. Jeffrey Cummings serves as Director of the Chamber-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas and is Director Emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings is the originator of the Neuropsychiatric Inventory (NPI), a widely used clinical test battery that has been translated in over 75 languages and used around the world to assess and monitor dementia-related symptoms. Dr. Cummings has been recognized for his research leadership in Alzheimer’s disease with the prestigious Lifetime Achievement Award from the Alzheimer’s Association and is a recipient of numerous other honors, including from the Society for Behavioral and Cognitive Neurology, American Association of Geriatric Psychiatry, International Society of CNS Drug Development, and the American Geriatrics Society.

Dr. Henrik Zetterberg is a Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry at Sahlgrenska Academy at the University of Gothenburg. With a background in molecular biology and clinical chemistry, Dr. Zetterberg has spent the last 20 years focusing on the development of biomarkers for Alzheimer’s disease, Parkinson’s disease and other brain disorders. He has developed new diagnostic tests for Alzheimer’s disease, as well as new preclinical models. Dr. Zetterberg has received numerous prizes, including the Erik K. Fernström Prize for Junior Scientists and the Inga Sandeborg Prize for Research on Alzheimer’s Disease. He is professor of neurochemistry and head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, senior consultant in clinical chemistry at the Sahlgrenska University Hospital, professor of neurochemistry at University College London and the UK Dementia Research Institute and a Wallenberg Scholar.

Dr. Bruce Lamb serves as executive director of the Paul and Carole Stark Neurosciences Research Institute at Indiana University School of Medicine. Dr. Lamb is a world-expert on the biological underpinnings of Alzheimer’s disease and related dementia. He currently serves as chair of the medical and scientific advisory group and as a member of the Board of Directors of the Alzheimer’s Association. Dr. Lamb is an active member of the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment, which convenes the global Alzheimer’s disease and dementia science community around key research areas. He is responsible for launching the professional interest area tied to immunity. Dr. Lamb is also a board member of the Alzheimer’s Association Greater Indiana Chapter and is actively involved in advocacy to support increased research funding for Alzheimer’s disease.